NVCR [NASD]
NovoCure Limited
Index- P/E- EPS (ttm)-0.57 Insider Own1.10% Shs Outstand104.19M Perf Week22.58%
Market Cap7.04B Forward P/E- EPS next Y-0.63 Insider Trans-4.41% Shs Float90.49M Perf Month-10.18%
Income-58.90M PEG- EPS next Q-0.15 Inst Own78.80% Short Float8.98% Perf Quarter-9.40%
Sales537.90M P/S13.08 EPS this Y-819.30% Inst Trans3.15% Short Ratio11.87 Perf Half Y-12.91%
Book/sh4.18 P/B17.23 EPS next Y-13.00% ROA-5.20% Target Price102.75 Perf Year-67.67%
Cash/sh9.55 P/C7.55 EPS next 5Y- ROE-14.20% 52W Range56.39 - 226.14 Perf YTD-4.06%
Dividend- P/FCF195.42 EPS past 5Y18.20% ROI-5.20% 52W High-68.15% Beta0.94
Dividend %- Quick Ratio8.20 Sales past 5Y45.20% Gross Margin78.40% 52W Low27.74% ATR4.76
Employees1167 Current Ratio8.50 Sales Q/Q2.10% Oper. Margin-8.40% RSI (14)51.82 Volatility8.63% 6.37%
OptionableYes Debt/Eq1.29 EPS Q/Q-10.90% Profit Margin-10.90% Rel Volume0.65 Prev Close74.69
ShortableYes LT Debt/Eq1.29 EarningsApr 28 BMO Payout- Avg Volume684.60K Price72.03
Recom2.60 SMA201.04% SMA50-2.21% SMA200-16.93% Volume445,093 Change-3.56%
May-16-22Initiated H.C. Wainwright Buy $115
Feb-08-22Initiated Loop Capital Buy $200
Feb-02-22Upgrade Oppenheimer Perform → Outperform $98
Jan-20-22Upgrade Truist Hold → Buy $125
Jan-03-22Upgrade Evercore ISI Underperform → In-line $82
Jul-01-21Downgrade Mizuho Buy → Neutral
Apr-14-21Downgrade Wedbush Neutral → Underperform $159 → $154
Jan-25-21Reiterated Piper Sandler Overweight $140 → $225
Sep-23-20Initiated Northland Capital Outperform $200
Sep-18-20Downgrade Wells Fargo Overweight → Equal Weight $116
Sep-17-20Downgrade Truist Buy → Hold $108
Jun-01-20Resumed Oppenheimer Perform
May-01-20Downgrade Oppenheimer Outperform → Perform
Apr-09-20Downgrade Evercore ISI In-line → Underperform $58
Mar-05-20Upgrade Wells Fargo Equal Weight → Overweight $85 → $90
Jan-02-20Downgrade Evercore ISI Outperform → In-line $84 → $90
Jul-29-19Upgrade SunTrust Hold → Buy
Jul-26-19Downgrade Wedbush Outperform → Neutral $57 → $80
Jul-26-19Downgrade JP Morgan Overweight → Neutral $61 → $79
Mar-20-19Initiated SunTrust Hold
Jun-23-22 07:46AM  
Jun-21-22 08:00AM  
Jun-16-22 04:25PM  
Jun-13-22 09:03AM  
Jun-11-22 06:05AM  
Jun-03-22 08:00AM  
08:00AM  
May-28-22 06:55AM  
May-26-22 08:00AM  
May-23-22 12:26PM  
May-12-22 01:00PM  
May-02-22 06:02AM  
Apr-28-22 01:30PM  
08:35AM  
07:00AM  
Apr-22-22 04:00PM  
Apr-19-22 04:45PM  
Apr-14-22 05:52AM  
Apr-11-22 11:30AM  
Apr-08-22 12:08PM  
07:00AM  
06:00AM  
05:55AM  
Apr-03-22 06:10AM  
Apr-01-22 07:30AM  
Mar-25-22 07:50AM  
07:00AM  
Mar-24-22 04:00PM  
Mar-23-22 08:00AM  
Mar-13-22 06:04AM  
Mar-06-22 07:04AM  
Feb-28-22 07:00AM  
Feb-24-22 04:24PM  
02:00PM  
08:35AM  
07:05AM  
07:00AM  
Feb-20-22 06:04AM  
Feb-18-22 04:00PM  
Feb-17-22 03:03PM  
Feb-16-22 08:15AM  
Feb-08-22 09:38AM  
Feb-04-22 09:00AM  
08:08AM  
05:52AM  
Feb-03-22 05:45PM  
09:38AM  
Feb-02-22 01:38PM  
01:38PM  
01:38PM  
09:38AM  
Jan-30-22 06:10AM  
Jan-29-22 07:55AM  
Jan-27-22 01:38PM  
Jan-26-22 05:38PM  
Jan-20-22 11:43AM  
Jan-12-22 09:38AM  
Jan-10-22 04:24PM  
07:00AM  
Jan-08-22 11:00AM  
Jan-06-22 07:56AM  
Jan-04-22 08:00AM  
Dec-19-21 06:38AM  
Dec-17-21 08:38PM  
Dec-15-21 03:38PM  
Dec-07-21 04:11PM  
Dec-06-21 07:38PM  
08:11AM  
08:00AM  
Dec-03-21 08:10AM  
Dec-02-21 06:28AM  
Nov-23-21 07:30AM  
Nov-15-21 03:19PM  
07:31AM  
07:30AM  
Nov-13-21 06:04AM  
Oct-29-21 08:20AM  
Oct-28-21 05:01PM  
04:29PM  
08:55AM  
06:30AM  
06:30AM  
Oct-25-21 05:23PM  
Oct-21-21 03:03PM  
07:30AM  
Oct-17-21 06:04AM  
Oct-14-21 11:30AM  
Oct-12-21 10:00AM  
08:50AM  
Oct-11-21 05:03AM  
Oct-10-21 07:31AM  
Oct-06-21 11:16AM  
Oct-04-21 07:30AM  
07:30AM  
07:30AM  
Sep-14-21 08:34AM  
07:00AM  
Sep-09-21 11:12AM  
08:14AM  
Sep-02-21 06:00AM  
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HILLEMAN JERYL LDirectorJun 10Sale69.6140728,3312,537Jun 16 04:22 PM
Benaim ElyChief Medical OfficerMay 11Sale61.252,135130,76934,846May 12 04:30 PM
Benaim ElyChief Medical OfficerMay 10Sale65.162,070134,87736,981May 12 04:30 PM
Shah PriteshChief Commercial OfficerMar 09Sale71.193,669261,19683,187Mar 11 04:54 PM
Leonard Frank XChief Development OfficerMar 08Sale70.1074452,154102,295Mar 09 04:55 PM
Burke William PatrickChief Human Resources OfficerMar 08Sale70.101,03772,69455,991Mar 09 04:53 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerMar 08Sale70.102,923204,902165,102Mar 09 04:52 PM
Cordova AshleyChief Financial OfficerMar 08Sale70.1075953,20660,848Mar 09 04:51 PM
Longsworth Todd ChristopherGeneral CounselMar 08Sale70.102,339163,96462,462Mar 09 04:50 PM
DOYLE WILLIAM FExecutive ChairmanMar 08Sale70.102,385167,188552,013Mar 09 04:48 PM
Shah PriteshChief Commercial OfficerMar 08Sale70.102,481173,91881,908Mar 09 04:56 PM
Shah PriteshChief Commercial OfficerMar 07Sale69.555,294368,19884,389Mar 09 04:56 PM
Leonard Frank XChief Development OfficerMar 04Sale70.4155539,076103,039Mar 07 06:14 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerMar 04Sale70.412,569180,876168,025Mar 07 06:16 PM
Burke William PatrickChief Human Resources OfficerMar 04Sale70.411,02672,23857,028Mar 07 06:17 PM
Benaim ElyChief Medical OfficerMar 04Sale70.411,510106,31543,257Mar 07 06:18 PM
Shah PriteshChief Commercial OfficerMar 04Sale72.114,546327,79089,683Mar 07 06:23 PM
Cordova AshleyChief Financial OfficerMar 04Sale70.4155639,14661,607Mar 07 06:26 PM
Longsworth Todd ChristopherGeneral CounselMar 04Sale70.411,973138,91364,801Mar 07 06:28 PM
Cordova AshleyChief Financial OfficerMar 03Option Exercise14.615,04073,65665,888Mar 11 04:55 PM
Longsworth Todd ChristopherGeneral CounselMar 03Sale74.501,09481,50166,774Mar 07 06:28 PM
Cordova AshleyChief Financial OfficerMar 03Sale74.501,14985,59862,163Mar 07 06:26 PM
Shah PriteshChief Commercial OfficerMar 03Sale74.5099774,27594,229Mar 07 06:23 PM
Benaim ElyChief Medical OfficerMar 03Sale74.5080359,82244,767Mar 07 06:18 PM
Burke William PatrickChief Human Resources OfficerMar 03Sale74.5034125,40458,054Mar 07 06:17 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerMar 03Sale74.501,30196,922170,594Mar 07 06:16 PM
Leonard Frank XChief Development OfficerMar 03Sale74.5093069,283103,594Mar 07 06:14 PM
Burke William PatrickChief Human Resources OfficerJan 03Option Exercise10.4928,604299,99651,269Jan 05 04:52 PM
Burke William PatrickChief Human Resources OfficerJan 03Sale76.003,951300,26341,036Jan 05 04:52 PM
Danziger AsafChief Executive OfficerNov 26Buy102.444,974509,53913,276Nov 29 04:48 PM
Cordova AshleyChief Financial OfficerNov 02Sale107.2820922,42141,758Nov 03 04:11 PM
Shah PriteshChief Commercial OfficerSep 03Sale138.6850169,47773,512Sep 07 04:32 PM
Leonard Frank XChief Development OfficerSep 02Sale138.2354074,64587,153Sep 07 04:39 PM
Cordova AshleyChief Financial OfficerSep 02Sale138.23828114,45641,967Sep 07 04:37 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 02Sale138.2318125,020149,899Sep 07 04:35 PM
Shah PriteshChief Commercial OfficerSep 02Sale138.2315621,56474,013Sep 07 04:32 PM
Cordova AshleyChief Financial OfficerAug 12Option Exercise28.8236,6241,055,32954,019Aug 16 04:40 PM
Cordova AshleyChief Financial OfficerAug 12Sale140.9426,6243,752,28645,993Aug 16 04:40 PM
LEUNG GABRIELDirectorAug 05Option Exercise31.451,00031,45073,859Aug 06 04:39 PM
LEUNG GABRIELDirectorAug 05Sale152.501,000152,50072,859Aug 06 04:39 PM
Madden Martin J.DirectorAug 05Sale153.13345,206384Aug 06 04:44 PM
Shah PriteshChief Commercial OfficerAug 04Sale148.712,063306,78974,169Aug 06 04:41 PM
Leonard Frank XChief Development OfficerAug 03Sale149.4332849,01389,158Aug 04 05:20 PM
Benaim ElyChief Medical OfficerAug 03Sale150.1146469,65128,144Aug 04 04:59 PM
Shah PriteshChief Commercial OfficerAug 03Sale149.431,654247,15776,232Aug 04 05:09 PM
DOYLE WILLIAM FExecutive ChairmanAug 02Sale149.38995148,631554,398Aug 04 05:01 PM
Benaim ElyChief Medical OfficerAug 02Sale149.3853680,06728,608Aug 03 05:29 PM
Leonard Frank XChief Development OfficerAug 02Sale149.38713106,50789,486Aug 04 05:20 PM
Shah PriteshChief Commercial OfficerJul 31Option Exercise154.013,717572,45585,625Mar 11 04:54 PM
Benaim ElyChief Medical OfficerJul 30Option Exercise83.3065154,22829,795Aug 03 05:29 PM
Benaim ElyChief Medical OfficerJul 30Sale158.96651103,48329,144Aug 03 05:29 PM
LEUNG GABRIELDirectorJul 06Option Exercise31.451,00031,45073,859Jul 08 05:23 PM
LEUNG GABRIELDirectorJul 06Sale183.541,000183,54072,859Jul 08 05:23 PM